Gilead Sciences GILD
NASDAQ GILD
$146.12 +2.68 (+1.87%)
At close: Aug 21, 2026 · 4:00 PM EDT

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023)

Gilead Sciences' (GILD) quarterly Income from Non-Controlling Interests came in at -$12.0 million in Q4 2023, down 71.43% YoY from -$42.0 million in Q4 2022, and down 50.0% on a QoQ basis from -$8.0 million in Q3 2023.

Gilead Sciences (GILD) Income from Non-Controlling Interests (2009 - 2023) Analysis & Trends

Gilead Sciences (GILD) has 15 years of Income from Non-Controlling Interests data on file, last reported at -$12.0 million in Q4 2023.

  • Quarterly Income from Non-Controlling Interests fell 71.43% year-over-year to -$12.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$12.0 million (up 74.47% YoY) and the FY2023 annual result came in at -$52.0 million, down 100.0% from the prior year.
  • Income from Non-Controlling Interests declined to -$12.0 million in Q4 2023, from -$8.0 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$3.0 million in Q3 2019 to a low of -$26.0 million in Q1 2023.
  • A 5-year average of -$7.9 million and a median of -$7.0 million in 2019 frame the typical range for Income from Non-Controlling Interests.
  • Annual changes were most pronounced in 2019 — Income from Non-Controlling Interests plunged 800.0% — and 2022, when it jumped 50.0%.
  • Tracing GILD's Income from Non-Controlling Interests over 5 years: stood at -$7.0 million in 2019, then changed by 0.0% to -$7.0 million in 2020, then increased by 14.29% to -$6.0 million in 2021, then fell by 16.67% to -$7.0 million in 2022, then sank by 71.43% to -$12.0 million in 2023.
  • The last three Income from Non-Controlling Interests figures came in at -$12.0 million (Q4 2023), -$8.0 million (Q3 2023), and -$6.0 million (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn -
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.00 Mn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -2.00 Mn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn -7.00 Mn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 1.00 Mn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn -
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 10.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 741.95 Mn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn 39.52 Mn

Historic Data

Download Data
DateValue
Dec 31, 2023 -12.00 Mn
Sep 30, 2023 -8.00 Mn
Jun 30, 2023 -6.00 Mn
Mar 31, 2023 -26.00 Mn
Dec 31, 2022 -7.00 Mn
Sep 30, 2022 -3.00 Mn
Jun 30, 2022 -9.00 Mn
Mar 31, 2022 -7.00 Mn
Dec 31, 2021 -6.00 Mn
Sep 30, 2021 -6.00 Mn
Jun 30, 2021 -5.00 Mn
Mar 31, 2021 -7.00 Mn
Dec 31, 2020 -7.00 Mn
Sep 30, 2020 -7.00 Mn
Jun 30, 2020 -7.00 Mn
Mar 31, 2020 -13.00 Mn
Dec 31, 2019 -7.00 Mn
Sep 30, 2019 -3.00 Mn
Jun 30, 2019 -5.00 Mn
Mar 31, 2019 -7.00 Mn